Zyma Healthcare is hunting for a PR agency to work on its antiseptic
The company is understood to have shortlisted at least two agencies for
the business: Lowe Bell Good Relations and healthcare specialist Bates
Healthcom. Part of the Cordiant-owned advertising network Bates Dorland,
Bates Healthcom has handled Savlon’s pounds 2 million advertising
account since last October.
The brand, believed to represent in excess of pounds 50,000 in PR fees,
has been without an agency since the beginning of the year. Incumbent
Lynne Franks resigned the business after two years in order to take on
direct rival, Dettol - owned by one of its biggest clients, Reckitt and
Last April Reckitt and Colman handed Lynne Franks PR almost all its
over-the-counter pharmaceutical brands including Lemsip, Disprin,
Fybogel and Bonjela - with a combined fee value of more than pounds
200,000. The agency was, however, unable to take on Dettol, until it had
completed its work on Savlon.
Lynne Franks also works on Zyma brands Piz Buin (sun care products) and
Nicotinell (nicotine patches) but both agency and client dismissed any
suggestion that these would be affected by the change on Savlon.
‘Zyma are an incredibly understanding client,’ said Lynne Franks
managing director Samantha Royston. ‘They are happy to continue to
retain us for any piece of business which is not going to be in conflict
with Reckitt and Colman.’
Savlon brand manager Julie Green said there had been ‘no damage to our
working relationship’ with Lynne Franks.
She added: ‘We’re going through some repackaging at the moment and we
wouldn’t be looking for a PR agency unless we had something to shout
Early last year Zyma launched the Savlon Baby range comprising nappy
cream, lotion, bath and surface spray to sit alongside its core
products. Further development of the brand seems likely.
The move comes at an uncertain time for Zyma. Its parent Ciba is
currently involved in what is, at pounds 42 billion, the biggest
corporate merger in history, linking up with fellow Swiss
pharmaceuticals giant Sandoz to form the world’s second-largest drugs